Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Operating Income (2020 - 2025)

Barinthus Biotherapeutics' Operating Income history spans 6 years, with the latest figure at -$11.6 million for Q4 2025.

  • For Q4 2025, Operating Income rose 50.56% year-over-year to -$11.6 million; the TTM value through Dec 2025 reached -$70.6 million, down 3.8%, while the annual FY2025 figure was -$70.6 million, 3.8% down from the prior year.
  • Operating Income reached -$11.6 million in Q4 2025 per BRNS's latest filing, up from -$15.1 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $13.2 million in Q2 2022 to a low of -$26.3 million in Q2 2023.
  • Average Operating Income over 5 years is -$13.6 million, with a median of -$16.8 million recorded in 2021.
  • Peak YoY movement for Operating Income: surged 230.71% in 2022, then plummeted 3385.02% in 2023.
  • A 5-year view of Operating Income shows it stood at -$16.7 million in 2021, then tumbled by 50.55% to -$25.1 million in 2022, then rose by 20.34% to -$20.0 million in 2023, then decreased by 17.02% to -$23.4 million in 2024, then skyrocketed by 50.56% to -$11.6 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Operating Income are -$11.6 million (Q4 2025), -$15.1 million (Q3 2025), and -$23.3 million (Q2 2025).